OTCMKTS:EPRXF Eupraxia Pharmaceuticals (EPRXF) Stock Price, News & Analysis → Claim Your FREE 'AI Income Playbook' Now! (From The Oxford Club) (Ad) Free EPRXF Stock Alerts C$2.71 -0.05 (-1.81%) (As of 06/14/2024 ET) Add Compare Share Share Today's RangeC$2.64▼C$2.7650-Day RangeC$2.51▼C$3.0152-Week RangeC$2.93▼C$6.78Volume3,060 shsAverage Volume7,410 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetC$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Eupraxia Pharmaceuticals alerts: Email Address Ad The Oxford ClubClaim Your FREE "AI Income Playbook" Now!Income expert Marc Lichtenfeld has a special gift reserved just for you... It's his brand-new "AI Income Playbook" - and it's yours FREE!Click here now to claim your FREE copy of Marc's AI playbook. About Eupraxia Pharmaceuticals Stock (OTCMKTS:EPRXF)Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.Read More EPRXF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EPRXF Stock News HeadlinesMay 29, 2024 | theglobeandmail.comClosing Bell: Eupraxia Pharmaceuticals Inc down on Monday (EPRX)May 24, 2024 | msn.comEupraxia Pharmaceuticals expands trial of eosinophilic esophagitis therapyMay 21, 2024 | marketwatch.comEupraxia Pharmaceuticals Shares Pop After New Trial DataMay 18, 2024 | morningstar.comEupraxia Pharmaceuticals Inc Ordinary SharesApril 27, 2024 | markets.businessinsider.comEQS-News: CHEPLAPHARM closes financial year 2023 with record revenue and double-digit growthApril 20, 2024 | ca.finance.yahoo.comEupraxia Pharmaceuticals Inc (EPRX-WT.TO)April 11, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024April 11, 2024 | prnewswire.comEupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024April 3, 2024 | finance.yahoo.comEupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024April 1, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial ResultsMarch 29, 2024 | markets.businessinsider.comEQS-News: APONTIS PHARMA expects profitable growth again in 2024March 15, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 MillionMarch 12, 2024 | marketwatch.comEupraxia Pharma Shares Drop After Stock Offering PricesMarch 12, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - EPRXMarch 12, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering of $30 MillionMarch 11, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approximately $30 MillionMarch 1, 2024 | seekingalpha.comProfit Setback For Simcere Pharma In Novel Drugs QuestFebruary 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Morphic Holding (MORF) and Vertex Pharmaceuticals (VRTX)February 15, 2024 | msn.comWest Pharmaceutical reports mixed Q4 results; initiates FY24 outlookFebruary 15, 2024 | reuters.comMedical equipment maker West Pharmaceutical forecasts weak annual resultsFebruary 6, 2024 | marketwatch.comVertex Pharmaceuticals 4Q Net, Revenue Beat EstimatesFebruary 5, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic EsophagitisFebruary 1, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IARJanuary 30, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the KneeJanuary 8, 2024 | finance.yahoo.comEupraxia Pharmaceuticals Announces Filing of Preliminary MJDS Base Shelf ProspectusSee More Headlines Receive EPRXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:EPRXF CUSIPN/A CIKN/A Webwww.eupraxiapharma.com Phone250 590 3968FaxN/AEmployees21Year FoundedN/APrice Target and Rating Average Stock Price TargetC$18.00 High Stock Price TargetC$18.00 Low Stock Price TargetC$18.00 Potential Upside/Downside+563.0%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. James A. Helliwell FRCPC (Age 50)M.D., CEO & Director Comp: $463.72kMr. Bruce G. Cousins C.A. (Age 63)CPA, President & CFO Comp: $311.61kDr. Amanda Malone Ph.D. (Age 43)Chief Scientific Officer Comp: $343.63kMr. Paul Anthony Brennan B.Sc.M.Sc., Chief Business OfficerDr. Mark M. Kowalski M.D. (Age 69)Ph.D., Chief Medical Officer Key Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors EPRXF Stock Analysis - Frequently Asked Questions What is Eupraxia Pharmaceuticals' stock price target for 2024? 0 equities research analysts have issued 1 year target prices for Eupraxia Pharmaceuticals' stock. Their EPRXF share price targets range from C$18.00 to C$18.00. On average, they predict the company's share price to reach C$18.00 in the next year. This suggests a possible upside of 563.0% from the stock's current price. View analysts price targets for EPRXF or view top-rated stocks among Wall Street analysts. How have EPRXF shares performed in 2024? Eupraxia Pharmaceuticals' stock was trading at C$4.16 at the beginning of 2024. Since then, EPRXF stock has decreased by 34.8% and is now trading at C$2.71. View the best growth stocks for 2024 here. How do I buy shares of Eupraxia Pharmaceuticals? Shares of EPRXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:EPRXF) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersPresident KamalaThe sneaky (yet 100% legal) way for Obama to return to power The ONLY way Democrats can keep the White Hous...Stansberry Research | SponsoredDiscover How to Turn $10,000 into $1 MillionToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRIL...Paradigm Press | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.